ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pulmonary Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,608Medicare Part D Prescriptions Filled, Including Refills
$515K Total Retail Price of All Prescriptions
395 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
42% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
SIMVASTATIN 602 463
LISINOPRIL 444 341
AMLODIPINE BESYLATE 418 351
LEVOTHYROXINE SODIUM 375 271
METFORMIN HCL 222 179
HYDROCHLOROTHIAZIDE 206 153
METOPROLOL TARTRATE 189 146
OMEPRAZOLE 156 102
PREDNISONE 148 108
FUROSEMIDE 147 118
METOPROLOL SUCCINATE 135 129
HYDROCODONE-ACETAMINOPHEN 130 93 S3
ATENOLOL 129 95
ADVAIR DISKUS 127 106
WARFARIN SODIUM 123 96
CITALOPRAM HBR 122 91
COMBIVENT 121 107
ALENDRONATE SODIUM 118 102
PROAIR HFA 116 64
SINGULAIR 115 72
ZOLPIDEM TARTRATE 113 98
SERTRALINE HCL 112 98
NEXIUM 99 70
GABAPENTIN 97 80
LANTUS 96 70
SYNTHROID 95 69
ATORVASTATIN CALCIUM 93 78
CEFUROXIME 89 69
DOXAZOSIN MESYLATE 81 56
TRAMADOL HCL 80 41
TAMSULOSIN HCL 76 46
TRICOR 74 23
PRAVASTATIN SODIUM 73 26
JANUVIA 72 47
MONTELUKAST SODIUM 69 48
POTASSIUM CHLORIDE 67 36
LOSARTAN POTASSIUM 63 58
ALLOPURINOL 60 46
CIPROFLOXACIN HCL 60 53
PANTOPRAZOLE SODIUM 59 53
VENTOLIN HFA 54 49
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 30, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.